Canaccord lowered the firm’s price target on Zimmer Biomet to $120 from $130 and keeps a Hold rating on the shares. The firm updated its model following Q2 results and lowered the target by applying a greater discount to the peer group versus their prior valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $128 from $138 at Raymond James
- Zimmer Biomet price target lowered to $115 from $140 at Deutsche Bank
- Zimmer Biomet price target lowered to $145 from $155 at Baird
- Zimmer Biomet price target lowered to $145 from $155 at Oppenheimer
- Zimmer Biomet price target lowered to $112 from $132 at Wells Fargo